Study of intestinal transporters and their role in drug absorption

Abstract

Charles University, Faculty of Pharmacy in Hradec Kralove Training Workplace Department of Pharmacology and Toxicology Doctoral Degree Program Pharmacology and Toxicology Candidate Mgr. Martin Huliciak Supervisor Assoc. Prof. PharmDr. Lukas Cerveny, PhD. Advisor PharmDr. Ivan Vokral, PhD. Title of Doctoral Thesis Study of intestinal transporters and their role in drug absorption Oral drug administration is a widely accepted method due to its convenience and cost- effectiveness, with the small intestine playing a crucial role in drug absorption, thus affecting bioavailability and serving as a potential site for drug-drug interactions (DDIs). Efflux drug transporters such as P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), along with metabolizing enzymes such as cytochrome P450 3A4 (CYP3A4) at the intestinal barrier, significantly contribute to DDIs. Risk factors for DDIs include comorbidities, advanced age, and polypharmacotherapy. People living with HIV requiring antiretroviral therapy (ART) are particularly susceptible to DDIs, especially when co-infected with HCV. Antivirals, commonly used in ART and in the treatment of HCV infection, can interact with efflux transporters and CYP enzymes, affecting drug efficacy and safety. Therefore, this study mainly focuses on the DDIs of...

Univerzita Karlova, Farmaceuticka fakulta v Hradci Kralove Školiace pracovisko Katedra farmakologie a toxikologie Doktorský studijný program Farmakologie a toxikologie Kandidát Mgr. Martin Huliciak Školiteľ doc. PharmDr. Lukas Červený, PhD. Konzultant PharmDr. Ivan Vokral, PhD. Názov dizertačnej práce Študium crevných transporterov a ich rolý pri absorpcii lieciv Peroralne podavanie liekov je siroko akceptovanou metodou vďaka svojej praktickosti a ekonomickej výhodnosti, pricom tenke crevo zohrava kľucovu ulohu pri absorpcii liekov, cím ovplývnuje biologicku dostupnosť a sluzi ako potencialne miesto pre interakcie medzi liekmi (DDIs). K DDIs významne prispievaju efluxne transporterý lieciv, ako je P- glýkoproteín (ABČB1) a proteín rezistencie rakoviný prsníka (ABČG2), spolu s metabolizujucimi enzýmami, ako je cýtochrom P450 3A4 (ČYP3A4) na crevnej bariere. Medzi rizikove faktorý DDIs patria komorbiditý, pokrocilý vek a polýfarmakoterapia. Pacienti zijuci s HIV výzadujuci antiretrovírusovu liecbu (ART) su obzvlasť nachýlní na DDIs, najma ak su sucasne infikovaní HČV. Antivirotika, ktore sa bezne pouzívaju pri ART a liecbe infekcie HČV, mozu interagovať s efluxnými transportermi a enzýmami ČYP, co ovplývnuje ucinnosť a bezpecnosť liekov. Tato studia sa preto zameriava najma na DDIs antivirotík na...